Spero Therapeutics, Inc. (SPRO)
Stock Price:
$13.11 USD
-0.33 (-2.46%)
Updated Oct 30, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
340.47M |
| Revenue (ttm) |
11.70M |
| Net Income (ttm) |
-83.46M |
| Shares Out |
25.97M |
| EPS (ttm) |
-4.31 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 30, 2020 |
| Last Price |
$13.11 |
| Previous Close |
$13.44 |
| Change ($) |
-0.33 |
| Change (%) |
-2.46% |
| Day's Open |
13.45 |
| Day's Range |
13.00 - 13.49 |
| Day's Volume |
145,370 |
| 52-Week Range |
5.25 - 14.60 |
More Stats
| Market Cap |
340.47M |
| Enterprise Value |
274.67M |
| Earnings Date (est) |
Nov 5, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
25.97M |
| Float |
21.14M |
| EPS (basic) |
-4.36 |
| EPS (diluted) |
-4.31 |
| FCF / Share |
-3.66 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.78M |
| Short Ratio |
5.22 |
| Short % of Float |
8.42% |
| Beta |
1.64 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
29.10 |
| PB Ratio |
4.66 |
| Revenue |
11.70M |
| Operating Income |
-85.17M |
| Net Income |
-83.46M |
| Free Cash Flow |
-75.49M |
| Net Cash |
65.80M |
| Net Cash / Share |
2.53 |
| Gross Margin |
-407.04% |
| Operating Margin |
-727.84% |
| Profit Margin |
-713.30% |
| FCF Margin |
-645.17% |
| ROA |
-48.38% |
| ROE |
-91.03% |
| ROIC |
-210.40% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (6)
| Buy |
6 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$30.83*
(135.16% upside)
Low
16.0
Current: $13.11
High
70.0
Target: 30.83
*Average 12-month price target from 6 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|
| Revenue | 18.15 | 3.97 | 1.98 | 0.34 | - |
| Revenue Growth | 357.56% | 100.4% | 490.75% | - | - |
| Gross Profit | 18.15 | 3.97 | 1.98 | 0.34 | - |
| Operating Income | -63.22 | -42.81 | -41.73 | -33.22 | -13.33 |
| Net Income | -60.93 | -41.66 | -38.74 | -25.49 | -13.15 |
| Shares Outstanding | 18.16 | 16.00 | 2.59 | 0.31 | 0.25 |
| Earnings Per Share | -3.35 | -2.60 | -17.82 | -95.87 | -53.11 |
| Operating Cash Flow | -50.02 | -39.63 | -39.11 | -28.96 | -9.61 |
| Capital Expenditures | -0.31 | -2.44 | -0.03 | -0.83 | -0.23 |
| Free Cash Flow | -50.33 | -42.06 | -39.14 | -29.79 | -9.84 |
| Cash & Equivalents | 82.05 | 115 | 87.54 | 10.57 | 5.89 |
| Total Debt | 5.55 | - | - | - | - |
| Net Cash / Debt | 76.50 | 115 | 87.54 | 10.57 | 5.89 |
| Assets | 106 | 129 | 93.48 | 13.77 | 7.18 |
| Liabilities | 31.53 | 13.15 | 8.52 | 7.41 | 7.43 |
| Book Value | 74.57 | 116 | 84.60 | -45.44 | -18.10 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Spero Therapeutics, Inc. |
| Country |
United States |
| Employees |
57 |
| CEO |
Ankit A. Mahadevia |
Stock Information
| Ticker Symbol |
SPRO |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: SPRO |
| IPO Date |
November 2, 2017 |
Description
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. Its product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative infections in the hospital; and SPR720, an oral antibiotic for the treatment of pulmonary non-tuberculous mycobacterial disease. Spero Therapeutics, Inc. has license agreement with Meiji Seika Pharma Company to support the development of tebipenem HBr; collaboration agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.